Sustainable Development Goals
17 Rooms: Supporting ‘big ideas’ for people and planet
On June 27, the Engelberg Center for Health Care Reform at Brookings hosted the State of Biomedical Innovation Conference in Washington, DC. Designed to bring together diverse stakeholders and senior thought leaders from across the biomedical enterprise, this event engaged participants in discussion on the health of biomedical innovation in the United States, obstacles to innovation, policy options for overcoming those obstacles, and key metrics that can be used to evaluate whether the U.S. biomedical enterprise is effectively delivering new and innovative medical products to the patients who need them.
Panelists included distinguished experts, industry leaders, policymakers, and regulators. After each panel, participants took audience questions.
Sen. Michael Bennet Delivers Keynote Address at State of Biomedical Innovation Event
Strategies for Stimulating Biomedical Innovation through Policy
Measuring the Health of the U.S. Biomedical Innovation Enterprise
Agenda
-
June 27
-
Measuring the Health of the U.S. Biomedical Innovation Enterprise
11:00 am
MAMurray Aitken Senior Vice President - IMS HealthMDMark DeemHGHenry Grabowski Professor Emeritus and Director, Program in Pharmaceutical Health Economics - Duke UniversityJLJonathan Leff Partner - Deerfield Management -
Strategies for Stimulating Biomedical Innovation through Policy
9:45 am
FCFrancis Collins Director - National Institutes of HealthRADRonald A. DePinho President - The University of Texas MD Anderson Cancer CenterMHMargaret Hamburg Commissioner - U.S. Food and Drug AdministrationKSKevin Sharer President of the Board - Amgen, Inc. -
Reflection on 50 Years of Progress in Biomedical Innovation
9:15 am
-
